Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.62 |
| ▸ | MEN1 | O00255 | 8/20 | 0.62 |
| ▸ | MAPT | P10636 | 6/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 12/20 | 0.60 |
| ▸ | RAB9A | P51151 | 11/20 | 0.60 |
| ▸ | TP53 | P04637 | 4/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.56 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.56 |
| ▸ | RELA | Q04206 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19748087 | 0.80 | PCSK9 (1.00) | PCSK9KMT2ASMN1; SMN2MEN1MAPT | |
| SCHEMBL19746324 | 0.78 | NPC1 (0.76) | PCSK9KMT2ASMN1; SMN2MEN1MAPT | |
| SCHEMBL31613770 | 0.78 | NPC1 (0.76) | PCSK9KMT2ASMN1; SMN2MEN1MAPT | |
| SCHEMBL19746581 | 0.78 | PCSK9 (0.70) | PCSK9KMT2ASMN1; SMN2MEN1MAPT | |
| SCHEMBL15798260 | 0.76 | NPC1 (1.00) | PCSK9KMT2ASMN1; SMN2MEN1MAPT | |
| SCHEMBL15654375 | 0.74 | HDAC2 (0.73) | PCSK9KMT2ASMN1; SMN2MEN1MAPT | |
| SCHEMBL5866982 | 0.74 | NPC1 (1.00) | KMT2ASMN1; SMN2MEN1MAPTKDM4E | |
| SCHEMBL15653761 | 0.74 | HDAC2 (0.66) | PCSK9KMT2ASMN1; SMN2MEN1NPC1 | |
| SCHEMBL7567703 | 0.73 | NPC1 (0.80) | KMT2ASMN1; SMN2MEN1MAPTKDM4E | |
| SCHEMBL3614041 | 0.72 | MMP2 (0.69) | KMT2ASMN1; SMN2MEN1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3471714-B1 | ANTI-PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (ANTI-PCSK9) COMPOUNDS AND METHODS OF USING THE SAME IN THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES | SHIFA BIOMEDICAL CORP (US) | 2025-06-11 | — | — | EP | claimed |
| CN-109475521-B | Anti-proprotein convertase subtilisin Kexin type 9 (anti-PCSK 9) compounds and methods of use thereof for treating and/or preventing cardiovascular diseases | 实发生物医学公司 | 2022-11-15 | — | — | CN | claimed |
| US-10947220-B2 | Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases | SHIFA BIOMEDICAL CORPORATION (US) | 2021-03-16 | — | — | US | claimed |
| US-10899748-B2 | Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases | SHIFA BIOMEDICAL CORPORATION (US) | 2021-01-26 | — | — | US | claimed |
| US-20200262822-A1 | Anti-Proprotein Convertase Subtilisin Kexin Type 9 (Anti-PCSK9) Compounds and Methods of Using the Same in the Treatment and/or Prevention of Cardiovascular Diseases | SHIFA BIOMEDICAL CORPORATION | 2020-08-20 | — | — | US | claimed |
| US-20190270729-A1 | Anti-Proprotein Convertase Subtilisin Kexin Type 9 (Anti-PCSK9) Compounds and Methods of Using the Same in the Treatment and/or Prevention of Cardiovascular Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-09-05 | — | — | US | claimed |
| EP-3471714-A1 | ANTI-PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (ANTI-PCSK9) COMPOUNDS AND METHODS OF USING THE SAME IN THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES | Shifa Biomedical Corporation (US) | 2019-04-24 | — | — | EP | claimed |
| WO-2017222953-A1 | ANTI-PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (ANTI-PCSK9) COMPOUNDS AND METHODS OF USING THE SAME IN THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES | SHIFA BIOMEDICAL CORPORATION (US) | 2017-12-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10899748-B2 | Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases | PCSK9, PCSK6, PCSK7 | PCSK9 1/4885KMT2A 2640/4885SMN1; SMN2 4671/4885 |
| US-20200262822-A1 | Anti-Proprotein Convertase Subtilisin Kexin Type 9 (Anti-PCSK9) Compounds and Methods of Using the Same in the Treatment and/or Prevention of Cardiovascular Diseases | PCSK9, PCSK6, PCSK7 | PCSK9 1/4885KMT2A 2640/4885SMN1; SMN2 4671/4885 |
| US-20190270729-A1 | Anti-Proprotein Convertase Subtilisin Kexin Type 9 (Anti-PCSK9) Compounds and Methods of Using the Same in the Treatment and/or Prevention of Cardiovascular Diseases | PCSK9, PCSK6, PCSK7 | PCSK9 1/4885KMT2A 2640/4885SMN1; SMN2 4671/4885 |
| US-10947220-B2 | Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases | PCSK9, PCSK6, PCSK7 | PCSK9 1/4885KMT2A 2640/4885SMN1; SMN2 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.